User:Mr. Ibrahem/Deflazacort

Mr. Ibrahem/Deflazacort
Clinical data
Trade names	Calcort, Emflaza, others
AHFS/Drugs.com	Monograph
Routes of; administration	By mouth
Drug class	Glucocorticoid
Legal status
Legal status	UK: POM (Prescription only); US: ℞-only;
Pharmacokinetic data
Protein binding	40%
Metabolism	By plasma esterases, to active metabolite
Elimination half-life	1.1–1.9 hours (metabolite)
Excretion	Kidney (70%) and fecal (30%)
Identifiers
	IUPAC name (11β,16β)-21-(Acetyloxy)-11-hydroxy-2′-methyl-5′H-pregna-1,4-dieno[17,16-d]oxazole-3,20-dione;
Chemical and physical data
Formula	C25H31NO6
Molar mass	441.524 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES O=C(OCC(=O)[C@]25/N=C(\O[C@@H]5C[C@H]1[C@H]4[C@H]([C@@H](O)C[C@@]12C)[C@]/3(/C=C\C(=O)\C=C\3CC4)C)C)C;
	InChI InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1 ; Key:FBHSPRKOSMHSIF-GRMWVWQJSA-N ;
	(what is this?) (verify)

Deflazacort, sold under the trade name Calcort among others, is a glucocorticoid used to treat allergic disorders and inflammatory disorders.^[1] It may also be used for Duchenne muscular dystrophy.^[2] It is taken by mouth.^[1]

Common side effects include weight gain, upper respiratory tract infection, increased hair growth, red skin, and irritability.^[2] Other side effects may include infection, adrenal insufficiency, Cushing syndrome, high blood sugar, anaphylaxis, blood clots, and toxic epidermal necrolysis.^[2] Deflazacort 6 mg has a similar anti-inflammatory effect as prednisone 5 mg.^[1]

Deflazacort was patented in 1965 and approved for medical use in 1985.^[3] In the United Kingdom 60 tablets of 6 mg costs the NHS about £16 as of 2021.^[1] In the United States this amount costs about 4,100 USD.^[4]

References[edit]

^ ^a ^b ^c ^d ^e ^f BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 714. ISBN 978-0857114105.
^ ^a ^b ^c ^d "Deflazacort Monograph for Professionals". Drugs.com. Archived from the original on 12 August 2020. Retrieved 22 December 2021.
^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 486. ISBN 9783527607495. Archived from the original on 2021-08-28. Retrieved 2021-07-01.
^ "Emflaza Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 14 August 2020. Retrieved 22 December 2021.

[BNF81-1] ^ ^a ^b ^c ^d ^e ^f BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 714. ISBN 978-0857114105.

[AHFS2021-2] "Deflazacort Monograph for Professionals". Drugs.com. Archived from the original on 12 August 2020. Retrieved 22 December 2021.

[Fis2006-3] Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 486. ISBN 9783527607495. Archived from the original on 2021-08-28. Retrieved 2021-07-01.

[4] "Emflaza Prices, Coupons & Patient Assistance Programs". Drugs.com. Archived from the original on 14 August 2020. Retrieved 22 December 2021.

[1]

[2]

[3]

[4]